Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Molecular Variants and Their Risks for Malignancy in Cytologically Indeterminate Thyroid Nodules.

Goldner W, Angell TE, McAdoo SL, Babiarz J, Sadow PM, Nabhan F, Nasr C, Kloos RT.

Thyroid. 2019 Aug 30. doi: 10.1089/thy.2019.0278. [Epub ahead of print]

PMID:
31469053
2.

Thyroid Nodules and Thyroid Cancer in the Pregnant Woman.

Angell TE, Alexander EK.

Endocrinol Metab Clin North Am. 2019 Sep;48(3):557-567. doi: 10.1016/j.ecl.2019.05.003. Epub 2019 Jun 11. Review.

PMID:
31345523
3.

A Cohort Analysis of Clinical and Ultrasound Variables Predicting Cancer Risk in 20,001 Consecutive Thyroid Nodules.

Angell TE, Maurer R, Wang Z, Kim MI, Alexander CA, Barletta JA, Benson CB, Cibas ES, Cho NL, Doherty GM, Doubilet PM, Frates MC, Gawande AA, Krane JF, Marqusee E, Moore FD, Nehs MA, Larsen PR, Alexander EK.

J Clin Endocrinol Metab. 2019 Jul 16. pii: jc.2019-00664. doi: 10.1210/jc.2019-00664. [Epub ahead of print]

PMID:
31310316
4.

Differences in Thyroid Nodule Cytology and Malignancy Risk Between Children and Adults.

Cherella CE, Angell TE, Richman DM, Frates MC, Benson CB, Moore FD, Barletta JA, Hollowell M, Smith JR, Alexander EK, Cibas ES, Wassner AJ.

Thyroid. 2019 Aug;29(8):1097-1104. doi: 10.1089/thy.2018.0728.

PMID:
31298618
5.

Getting more out of molecular testing for indeterminate thyroid nodules.

Angell TE.

Cancer Cytopathol. 2019 Sep;127(9):555-556. doi: 10.1002/cncy.22129. Epub 2019 Jun 25. No abstract available.

PMID:
31237737
6.

The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor-Related Thyroid Disorders.

Ma C, Hodi FS, Giobbie-Hurder A, Wang X, Zhou J, Zhang A, Zhou Y, Mao F, Angell TE, Andrews CP, Hu J, Barroso-Sousa R, Kaiser UB, Tolaney SM, Min L.

Cancer Immunol Res. 2019 Jul;7(7):1214-1220. doi: 10.1158/2326-6066.CIR-18-0613. Epub 2019 May 14.

PMID:
31088848
7.

The Impact of Hashimoto Thyroiditis on Thyroid Nodule Cytology and Risk of Thyroid Cancer.

Silva de Morais N, Stuart J, Guan H, Wang Z, Cibas ES, Frates MC, Benson CB, Cho NL, Nehs MA, Alexander CA, Marqusee E, Kim MI, Lorch JH, Barletta JA, Angell TE, Alexander EK.

J Endocr Soc. 2019 Mar 5;3(4):791-800. doi: 10.1210/js.2018-00427. eCollection 2019 Apr 1.

8.

Independent Comparison of the Afirma Genomic Sequencing Classifier and Gene Expression Classifier for Cytologically Indeterminate Thyroid Nodules.

Angell TE, Heller HT, Cibas ES, Barletta JA, Kim MI, Krane JF, Marqusee E.

Thyroid. 2019 May;29(5):650-656. doi: 10.1089/thy.2018.0726. Epub 2019 Mar 22.

PMID:
30803388
9.

Effect of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP) on Malignancy Rates in Thyroid Nodules: How to Counsel Patients on Extent of Surgery.

Lindeman BM, Nehs MA, Angell TE, Alexander EK, Gawande AA, Moore FD Jr, Doherty GM, Cho NL.

Ann Surg Oncol. 2019 Jan;26(1):93-97. doi: 10.1245/s10434-018-6932-5. Epub 2018 Oct 19.

PMID:
30341576
10.

Natural History and Outcomes of Cytologically Benign Thyroid Nodules in Children.

Cherella CE, Feldman HA, Hollowell M, Richman DM, Cibas ES, Smith JR, Angell TE, Wang Z, Alexander EK, Wassner AJ.

J Clin Endocrinol Metab. 2018 Sep 1;103(9):3557-3565. doi: 10.1210/jc.2018-00895.

11.

Performance of a Genomic Sequencing Classifier for the Preoperative Diagnosis of Cytologically Indeterminate Thyroid Nodules.

Patel KN, Angell TE, Babiarz J, Barth NM, Blevins T, Duh QY, Ghossein RA, Harrell RM, Huang J, Kennedy GC, Kim SY, Kloos RT, LiVolsi VA, Randolph GW, Sadow PM, Shanik MH, Sosa JA, Traweek ST, Walsh PS, Whitney D, Yeh MW, Ladenson PW.

JAMA Surg. 2018 Sep 1;153(9):817-824. doi: 10.1001/jamasurg.2018.1153.

12.

Risk Factors for New Hypothyroidism During Tyrosine Kinase Inhibitor Therapy in Advanced Nonthyroidal Cancer Patients.

Lechner MG, Vyas CM, Hamnvik OR, Alexander EK, Larsen PR, Choueiri TK, Angell TE.

Thyroid. 2018 Apr;28(4):437-444. doi: 10.1089/thy.2017.0579.

PMID:
29652599
13.

Hypothyroidism During Tyrosine Kinase Inhibitor Therapy Is Associated with Longer Survival in Patients with Advanced Nonthyroidal Cancers.

Lechner MG, Vyas CM, Hamnvik OR, Alexander EK, Larsen PR, Choueiri TK, Angell TE.

Thyroid. 2018 Apr;28(4):445-453. doi: 10.1089/thy.2017.0587.

PMID:
29652597
14.

POSITIVE THYROTROPIN RECEPTOR ANTIBODIES IN PATIENTS WITH TRANSIENT THYROTOXICOSIS.

Angell TE, Van Benschoten O, Cohen DA, Haas AV, Alexander EK, Marqusee E.

Endocr Pract. 2018 Jun;24(6):512-516. doi: 10.4158/EP-2018-0059. Epub 2018 Apr 6.

PMID:
29624097
15.

Unique Cytologic Features of Thyroiditis Caused by Immune Checkpoint Inhibitor Therapy for Malignant Melanoma.

Angell TE, Min L, Wieczorek TJ, Hodi FS.

Genes Dis. 2018 Mar;5(1):46-48. doi: 10.1016/j.gendis.2017.11.002. Epub 2017 Nov 21.

16.

Quantitative Analysis of the Benefits and Risk of Thyroid Nodule Evaluation in Patients ≥70 Years Old.

Wang Z, Vyas CM, Van Benschoten O, Nehs MA, Moore FD Jr, Marqusee E, Krane JF, Kim MI, Heller HT, Gawande AA, Frates MC, Doubilet PM, Doherty GM, Cho NL, Cibas ES, Benson CB, Barletta JA, Zavacki AM, Larsen PR, Alexander EK, Angell TE.

Thyroid. 2018 Apr;28(4):465-471. doi: 10.1089/thy.2017.0655. Epub 2018 Apr 2.

PMID:
29608439
17.

Reasons Associated with Total Thyroidectomy as Initial Surgical Management of an Indeterminate Thyroid Nodule.

Angell TE, Vyas CM, Barletta JA, Cibas ES, Cho NL, Doherty GM, Gawande AA, Howitt BE, Krane JF, Marqusee E, Strickland KC, Alexander EK, Moore FD Jr, Nehs MA.

Ann Surg Oncol. 2018 May;25(5):1410-1417. doi: 10.1245/s10434-018-6421-x. Epub 2018 Mar 8.

PMID:
29520656
18.

Molecular Testing of Nodules with a Suspicious or Malignant Cytologic Diagnosis in the Setting of Non-Invasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP).

Strickland KC, Eszlinger M, Paschke R, Angell TE, Alexander EK, Marqusee E, Nehs MA, Jo VY, Lowe A, Vivero M, Hollowell M, Qian X, Wieczorek T, French CA, Teot LA, Cibas ES, Lindeman NI, Krane JF, Barletta JA.

Endocr Pathol. 2018 Mar;29(1):68-74. doi: 10.1007/s12022-018-9515-x.

PMID:
29396809
19.

Differential Growth Rates of Benign vs. Malignant Thyroid Nodules.

Angell TE, Vyas CM, Medici M, Wang Z, Barletta JA, Benson CB, Cibas ES, Cho NL, Doherty GM, Doubilet PM, Frates MC, Gawande AA, Heller HT, Kim MI, Krane JF, Marqusee E, Moore FD Jr, Nehs MA, Zavacki AM, Larsen PR, Alexander EK.

J Clin Endocrinol Metab. 2017 Dec 1;102(12):4642-4647. doi: 10.1210/jc.2017-01832.

PMID:
29040691
20.

A modified reporting approach for thyroid FNA in the NIFTP era: A 1-year institutional experience.

Mito JK, Alexander EK, Angell TE, Barletta JA, Nehs MA, Cibas ES, Krane JF.

Cancer Cytopathol. 2017 Nov;125(11):854-864. doi: 10.1002/cncy.21907. Epub 2017 Sep 13.

21.

RAS-positive thyroid nodules.

Angell TE.

Curr Opin Endocrinol Diabetes Obes. 2017 Oct;24(5):372-376. doi: 10.1097/MED.0000000000000354. Review.

PMID:
28639967
22.

The Flip Side of NIFTP: an Increase in Rates of Unfavorable Histologic Parameters in the Remainder of Papillary Thyroid Carcinomas.

Wong KS, Strickland KC, Angell TE, Nehs MA, Alexander EK, Cibas ES, Krane JF, Howitt BE, Barletta JA.

Endocr Pathol. 2017 Jun;28(2):171-176. doi: 10.1007/s12022-017-9476-5.

PMID:
28271380
23.

Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes.

Baca SC, Wong KS, Strickland KC, Heller HT, Kim MI, Barletta JA, Cibas ES, Krane JF, Marqusee E, Angell TE.

Cancer Cytopathol. 2017 May;125(5):313-322. doi: 10.1002/cncy.21827. Epub 2017 Feb 2.

24.

Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features Accounts for More Than Half of "Carcinomas" Harboring RAS Mutations.

Paulson VA, Shivdasani P, Angell TE, Cibas ES, Krane JF, Lindeman NI, Alexander EK, Barletta JA.

Thyroid. 2017 Apr;27(4):506-511. doi: 10.1089/thy.2016.0583. Epub 2017 Feb 24.

PMID:
28114855
25.

HIGH-DOSE BIOTIN TREATMENT FOR SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS MAY INTERFERE WITH THYROID ASSAYS.

Minkovsky A, Lee MN, Dowlatshahi M, Angell TE, Mahrokhian LS, Petrides AK, Melanson SE, Marqusee E, Woodmansee WW.

AACE Clin Case Rep. 2016 Fall;2(4):e370-e373.

26.

Clinical, Sonographic, and Pathological Characteristics of RAS-Positive Versus BRAF-Positive Thyroid Carcinoma.

Kakarmath S, Heller HT, Alexander CA, Cibas ES, Krane JF, Barletta JA, Lindeman NI, Frates MC, Benson CB, Gawande AA, Cho NL, Nehs M, Moore FD, Marqusee E, Kim MI, Larsen PR, Kwong N, Angell TE, Alexander EK.

J Clin Endocrinol Metab. 2016 Dec;101(12):4938-4944. Epub 2016 Sep 30.

27.

Noninvasive Follicular Variant of Papillary Thyroid Carcinoma and the Afirma Gene-Expression Classifier.

Wong KS, Angell TE, Strickland KC, Alexander EK, Cibas ES, Krane JF, Barletta JA.

Thyroid. 2016 Jul;26(7):911-5. doi: 10.1089/thy.2015.0644.

PMID:
27219469
28.

Systemic delivery of chTNT-3/CpG immunoconjugates for immunotherapy in murine solid tumor models.

Jang JK, Khawli LA, Canter DC, Hu P, Zhu TH, Wu BW, Angell TE, Li Z, Epstein AL.

Cancer Immunol Immunother. 2016 May;65(5):511-23. doi: 10.1007/s00262-016-1813-x. Epub 2016 Mar 9.

29.

Long- versus short-interval follow-up of cytologically benign thyroid nodules: a prospective cohort study.

Medici M, Liu X, Kwong N, Angell TE, Marqusee E, Kim MI, Alexander EK.

BMC Med. 2016 Jan 27;14:11. doi: 10.1186/s12916-016-0554-1.

30.

Circulating Myeloid-Derived Suppressor Cells Predict Differentiated Thyroid Cancer Diagnosis and Extent.

Angell TE, Lechner MG, Smith AM, Martin SE, Groshen SG, Maceri DR, Singer PA, Epstein AL.

Thyroid. 2016 Mar;26(3):381-9. doi: 10.1089/thy.2015.0289. Epub 2016 Feb 10.

31.

Bethesda Categorization of Thyroid Nodule Cytology and Prediction of Thyroid Cancer Type and Prognosis.

Liu X, Medici M, Kwong N, Angell TE, Marqusee E, Kim MI, Larsen PR, Cho NL, Nehs MA, Ruan DT, Gawande A, Moore F Jr, Barletta J, Krane JF, Cibas ES, Yang T, Alexander EK.

Thyroid. 2016 Feb;26(2):256-61. doi: 10.1089/thy.2015.0376. Epub 2015 Dec 16.

32.

The Influence of Patient Age on Thyroid Nodule Formation, Multinodularity, and Thyroid Cancer Risk.

Kwong N, Medici M, Angell TE, Liu X, Marqusee E, Cibas ES, Krane JF, Barletta JA, Kim MI, Larsen PR, Alexander EK.

J Clin Endocrinol Metab. 2015 Dec;100(12):4434-40. doi: 10.1210/jc.2015-3100. Epub 2015 Oct 14.

33.

Afirma Benign Thyroid Nodules Show Similar Growth to Cytologically Benign Nodules During Follow-Up.

Angell TE, Frates MC, Medici M, Liu X, Kwong N, Cibas ES, Kim MI, Marqusee E.

J Clin Endocrinol Metab. 2015 Nov;100(11):E1477-83. doi: 10.1210/jc.2015-2658. Epub 2015 Sep 9.

34.

The variable phenotype and low-risk nature of RAS-positive thyroid nodules.

Medici M, Kwong N, Angell TE, Marqusee E, Kim MI, Frates MC, Benson CB, Cibas ES, Barletta JA, Krane JF, Ruan DT, Cho NL, Gawande AA, Moore FD Jr, Alexander EK.

BMC Med. 2015 Aug 7;13:184. doi: 10.1186/s12916-015-0419-z.

35.

Localized LECT2 amyloidosis of the adrenal gland with coexisting MGUS: a diagnostic challenge.

Angell TE, Swaika A, Sood N, Goldfarb M, Siddiqi I, Ailawadhi S.

Ann Hematol. 2015 Sep;94(9):1603-4. doi: 10.1007/s00277-015-2419-7. Epub 2015 Jun 7. No abstract available.

PMID:
26048244
36.

Clinical features and hospital outcomes in thyroid storm: a retrospective cohort study.

Angell TE, Lechner MG, Nguyen CT, Salvato VL, Nicoloff JT, LoPresti JS.

J Clin Endocrinol Metab. 2015 Feb;100(2):451-9. doi: 10.1210/jc.2014-2850. Epub 2014 Oct 24.

PMID:
25343237
37.

MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro.

Angell TE, Lechner MG, Jang JK, LoPresti JS, Epstein AL.

Clin Cancer Res. 2014 Dec 1;20(23):6034-44. doi: 10.1158/1078-0432.CCR-14-0879. Epub 2014 Oct 7.

38.

BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration.

Angell TE, Lechner MG, Jang JK, Correa AJ, LoPresti JS, Epstein AL.

Thyroid. 2014 Sep;24(9):1385-93. doi: 10.1089/thy.2014.0134. Epub 2014 Jul 15.

39.

In search of an unstimulated thyroglobulin baseline value in low-risk papillary thyroid carcinoma patients not receiving radioactive iodine ablation.

Angell TE, Spencer CA, Rubino BD, Nicoloff JT, LoPresti JS.

Thyroid. 2014 Jul;24(7):1127-33. doi: 10.1089/thy.2013.0691. Epub 2014 May 22.

PMID:
24697314
40.

Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy.

Lechner MG, Karimi SS, Barry-Holson K, Angell TE, Murphy KA, Church CH, Ohlfest JR, Hu P, Epstein AL.

J Immunother. 2013 Nov-Dec;36(9):477-89. doi: 10.1097/01.cji.0000436722.46675.4a.

41.

Immune cell infiltration patterns and survival in head and neck squamous cell carcinoma.

Russell S, Angell T, Lechner M, Liebertz D, Correa A, Sinha U, Kokot N, Epstein A.

Head Neck Oncol. 2013 Feb 27;5(3):24.

42.

Survival signals and targets for therapy in breast implant-associated ALK--anaplastic large cell lymphoma.

Lechner MG, Megiel C, Church CH, Angell TE, Russell SM, Sevell RB, Jang JK, Brody GS, Epstein AL.

Clin Cancer Res. 2012 Sep 1;18(17):4549-59. doi: 10.1158/1078-0432.CCR-12-0101. Epub 2012 Jul 12.

Supplemental Content

Loading ...
Support Center